Glaukos Corporation

GKOS Healthcare Medical Devices

Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.

Revenue
+58.0%
EPS
+110.7%
Free cash flow
+411.2%
Total debt
−2.25%

Quarter to September 2026, against a year earlier

225.48 5.50 +2.50%
Market cap
$13.0B
P/E
0.0×
Fwd P/E
−803×
Dividend yield
—
F-score
3/9
Altman Z
15.20
Beneish M
−2.96
Dividend safety
n/a

Glaukos Corporation (GKOS) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Glaukos Corporation (GKOS) trades at a P/S ratio of 18.8×. Over the past ten years it has ranged from 1.1× (September 2015) to 23.3× (December 2024); the current reading is higher than 95% of that period. That is above the Medical Devices industry median of 2.5× and above the Healthcare sector median of 3.5×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2025 12.7× (38.31%)
FY2024 20.6× 73.89%
FY2023 11.9× 61.18%
FY2022 7.4× 4.89%
FY2021 7.0× (52.86%)
FY2020 14.9× 73.38%
FY2019 8.6× (21.54%)
FY2018 10.9× 87.18%
FY2017 5.8× (39.77%)
FY2016 9.7× 61.30%

Quarterly newest first

Period P/S ratio Change
Sep 2026 14.1× 4.80%
Jun 2026 13.4× 18.39%
Mar 2026 11.3× (10.97%)
Dec 2025 12.7× 27.72%
43 more quarters

Against its own ten years

Low 1.1× High 23.3×
Ten-year median 11.0×
Current reading's percentile 95

P/S ratio against peers

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on GKOS